Notably, studies of GLP-1 action in animals and humans have demonstrated that GLP-1 decreases renal inflammation and albuminuria, reduces the extent of myocardial injury, attenuates the severity of experimental stroke, lowers blood pressure and postprandial lipemia, and exhibits antiatherogenic activity in sensitized mouse models prone to the development of atherosclerosis (10). This evidence concerns the gene GLP1R and atherosclerosis.